How is Ilumya administered?
Medically reviewed by Drugs.com Last updated on Jun 19, 2018.
Official Answerby Drugs.com
Ilumya is given as a 100 milligram (mg) subcutaneous (under the skin) injection. The first two injections are given 4 weeks apart, followed by an injection once every 12 weeks. Each single-dose prefilled syringe of Ilumya contains 100 mg of tildrakizumab-asmn.
In March, 2018 the FDA approved Ilumya (tildrakizumab-asmn), a humanized interleukin-23 p19 subunit antagonist (anti-IL-23p19) monoclonal antibody for moderate-to-severe plaque psoriasis in adults who are candidates for systemic treatment or phototherapy (ultraviolet or UV light).
Related Medical Questions
- What are the new drugs for the treatment of plaque psoriasis?
- How does Ilumya work to treat psoriasis?
- What are the side effects of Ilumya?
- What is the difference between Amjevita and Humira?
- What is the difference between Erelzi and Enbrel?
- What is the difference between Renflexis and Remicade?
- What is the Siliq REMS Program?
- Ilumya Information for Consumers
- Ilumya Information for Healthcare Professionals (includes dosage details)
- Side Effects of Ilumya (detailed)